Christina M. Parrinello

Mar 21, 2023 | acsjournals.onlinelibrary.wiley.com | Ghassan Abou Alfa |Xiaoliang Wang |Christina M. Parrinello |Anala Gossai

Abstract Background Clinical trials suggest α-fetoprotein (AFP) reduction may be prognostic among patients with advanced hepatocellular carcinoma. However, the association of AFP reduction with outcomes in real-world settings is unclear. Methods Patients with advanced hepatocellular carcinoma between January 1, 2011, and June 30, 2021, first-line tyrosine kinase inhibitor, and baseline and posttreatment AFP values (closest to 8 ± 2 weeks after first-line initiation) were included.